Business context and reporting period
Filing identity: The supplied filing is Pieris Pharmaceuticals, Inc.’s Form 10-Q, not a filing for Pavella Therapeutics, Inc. It covers the quarter and six months ended June 30, 2023; filed August 10, 2023.
Pieris is a clinical-stage biotechnology company developing Anticalin-based therapeutics. It has no product-sales revenue and relies on collaboration, license, grant, and financing proceeds. In July 2023, it began exploring strategic transactions and partnerships and approved a workforce reduction of approximately 70%.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement figures are in millions unless stated otherwise.
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $20.1 | $3.7 | $22.0 | $14.7 |
| Operating expenses | $18.0 | $16.0 | $35.4 | $34.5 |
| Operating income (loss) | $2.1 | $(12.3) | $(13.4) | $(19.8) |
| Net income (loss) | $4.0 | $(10.3) | $(9.2) | $(15.4) |
| Operating cash flow | Not separately stated | Not separately stated | $(24.4) | $(38.2) |
- Q2 revenue included approximately $12.5 million recognized after Genentech discontinued two discovery programs and approximately $3.9 million from an AstraZeneca program discontinuation. These are not recurring product-sales revenues.
- Six-month R&D expense was $27.8 million; G&A was $7.7 million. The filing does not present a gross margin measure.
- At June 30, cash and cash equivalents were $44.9 million and short-term investments were $9.9 million, totaling approximately $54.9 million. Current assets were $66.5 million and current liabilities $34.4 million.
- Cash increased by $6.3 million in the first half, supported by $19.8 million of financing cash flow, including ATM stock sales; operating activities used $24.4 million. Investing cash flow was positive $10.5 million, mainly reflecting investment maturities.
- The balance sheet lists no conventional borrowings. Operating lease liabilities were approximately $12.8 million; the filing also estimates $3.9 million of lease expansion payments beginning in October 2024.
- Pieris sold 24.3 million shares through its ATM program in the first half for $20.3 million gross proceeds at an average price of $0.84 per share. Shares outstanding were 98.9 million at June 30, versus 74.5 million at year-end 2022.
Material changes versus the prior comparable period
- Q2 revenue rose substantially year over year, chiefly due to recognition of previously deferred collaboration revenue upon program discontinuations. For the first half, revenue increased 50% while operating expenses rose modestly.
- Q2 moved from a $10.3 million net loss to $4.0 million net income; the first-half net loss narrowed from $15.4 million to $9.2 million. Q2 profitability should be viewed in light of the nonrecurring collaboration revenue noted above.
- First-half operating cash use declined from $38.2 million to $24.4 million, while ATM proceeds increased from $6.6 million net in the prior-year period to $19.7 million net.
Outlook, commentary, risks and unusual items
- Management says available funds should support the company’s remaining limited operations for at least 12 months from the filing date, based on current plans and estimates. Pieris expects operating costs to fall as it limits research and development and pursues strategic options.
- The July 2023 strategic review has no announced timetable or definitive transaction. The company cautions that no transaction may occur, may not be on attractive terms, and may not increase shareholder value. If no transaction is completed, the board may consider dissolution and liquidation.
- AstraZeneca stopped elarekibep study dosing after nonclinical toxicology findings of respiratory-tract pathology, including inflammation-mediated lung tissue damage. AstraZeneca gave notice of termination effective October 15, 2023. Pieris recognized $3.5 million of related deferred revenue as current, for expected recognition in Q3.
- Pieris plans to stop future investment in PRS-220 phase 2a readiness and PRS-400 R&D, and opted out of U.S. co-development of PRS-344/S095012. It is seeking partnerships for PRS-220, PRS-400, and cinrebafusp alfa. The PRS-220 phase 1 study outcome was expected in the second half of 2023.
- The July workforce reduction is expected to incur approximately $3.4 million of severance and related costs in Q3; additional retention costs were not estimable in the filing.
- The Bavarian PRS-220 grant may require repayment of some or all amounts if program proceeds, a change of control, or another event affects continuation of the program. Grant funding was approximately €14.2 million in total.
- Nasdaq notified Pieris in May 2023 that it did not meet the $1.00 minimum bid-price requirement. The initial compliance deadline is November 13, 2023; failure to regain compliance could lead to delisting. The filing reports no material pending legal proceedings.
Important facts for investors to verify
- Confirm the filing belongs to Pieris Pharmaceuticals, Inc.; it does not match the requested company name.
- Assess the sustainability of revenue and the effect of the Genentech and AstraZeneca revenue recognition on reported Q2 profit.
- Track cash burn, ATM financing capacity and dilution, and whether the stated 12-month funding outlook remains valid after restructuring and transaction costs.
- Monitor strategic-review progress, partnership prospects, potential liquidation, and retention of personnel needed to complete a transaction.
- Review the elarekibep safety findings, AstraZeneca termination, Bavarian grant repayment exposure, lease commitments, and Nasdaq bid-price compliance.